The estimated Net Worth of Eric A Adams is at least 501 千$ dollars as of 20 February 2024. Mr Adams owns over 41,600 units of InMed Pharmaceuticals stock worth over 12,748$ and over the last 3 years he sold INM stock worth over 0$. In addition, he makes 488,436$ as Pres、 CEO & Director at InMed Pharmaceuticals.
Mr has made over 5 trades of the InMed Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 41,600 units of INM stock worth 14,976$ on 20 February 2024.
The largest trade he's ever made was buying 41,600 units of InMed Pharmaceuticals stock on 20 February 2024 worth over 14,976$. On average, Mr trades about 6,037 units every 63 days since 2021. As of 20 February 2024 he still owns at least 43,959 units of InMed Pharmaceuticals stock.
You can see the complete history of Mr Adams stock trades at the bottom of the page.
Eric A. Adams is the Pres, CEO & Director at InMed Pharmaceuticals.
As the Pres、 CEO & Director of InMed Pharmaceuticals, the total compensation of Mr Adams at InMed Pharmaceuticals is 488,436$. There are no executives at InMed Pharmaceuticals getting paid more.
Mr Adams is 57, he's been the Pres、 CEO & Director of InMed Pharmaceuticals since . There are 2 older and 3 younger executives at InMed Pharmaceuticals. The oldest executive at InMed Pharmaceuticals Inc. is Alexandra Diane-Janet Mancini, 68, who is the Sr. VP of Clinical & Regulatory Affairs.
Eric's mailing address filed with the SEC is C/O INMED PHARMACEUTICALS INC., 310-815 WEST HASTINGS ST., VANCOUVER, A1, V6C1B4.
Over the last 4 years, insiders at InMed Pharmaceuticals have traded over 43$ worth of InMed Pharmaceuticals stock and bought 153,613 units worth 127,277$ . The most active insiders traders include William J Garner、Eric A Adams、Andrew Hull. On average, InMed Pharmaceuticals executives and independent directors trade stock every 86 days with the average trade being worth of 3,718$. The most recent stock trade was executed by Alexandra Diane Janet Mancini on 31 July 2024, trading 240 units of INM stock currently worth 43$.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
InMed Pharmaceuticals executives and other stock owners filed with the SEC include: